in a multicentre double-blind randomised study comparing the effects of sulphinpyrazone 400 mg twice daily with those of placebo in patients after myocardial infarction 727 patients ( 365 on sulphinpyrazone , 362 on placebo ) were enrolled and followed up for 12-48 months ( mean 19.2 ) .
C0027051
myocardial infarction
C0038742
sulphinpyrazone